2000
T-Lymphocyte Subsets in HIV-Infected and High-Risk HIV-Uninfected Adolescents: Retention of Naive T Lymphocytes in HIV-Infected Adolescents
Douglas SD, Rudy B, Muenz L, Starr SE, Campbell DE, Wilson C, Holland C, Crowley-Nowick P, Vermund SH. T-Lymphocyte Subsets in HIV-Infected and High-Risk HIV-Uninfected Adolescents: Retention of Naive T Lymphocytes in HIV-Infected Adolescents. JAMA Pediatrics 2000, 154: 375-380. PMID: 10768676, DOI: 10.1001/archpedi.154.4.375.Peer-Reviewed Original ResearchConceptsHIV-negative youthHuman immunodeficiency virus-infected adolescentsT lymphocyte subsetsNaive CD8Total CD4Immune systemCell countHIV infectionAdolescent careAdolescent Medicine HIV/AIDS Research NetworkHuman immunodeficiency virus (HIV) infectionHealth ProjectActive antiretroviral therapyCohort of HIVPercentage of CD4HIV-negative controlsHIV-positive subjectsImmunodeficiency virus infectionAIDS Research NetworkHigh-risk HIVT lymphocyte responsesHIV-negative adolescentsNaive T lymphocytesMemory cell populationsSignificant increase
1998
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines
Connor RI, Korber B, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM. Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines. Journal Of Virology 1998, 72: 1552-1576. PMID: 9445059, PMCID: PMC124637, DOI: 10.1128/jvi.72.2.1552-1576.1998.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1Immunodeficiency virus type 1Virus type 1MN rgp120Antibody responseHIV-1Recombinant gp120 subunit vaccinePhase I/II clinical trialsCytotoxic T lymphocyte responsesType 1Immunoglobulin G antibody responseGp120 subunit vaccineSyncytium-inducing (SI) phenotypeT lymphocyte responsesG antibody responseClade B virusesInducing (NSI) phenotypeInfected vaccineesNSI strainsPlacebo recipientsVaccine recipientsViral burdenPlacebo vaccineAntibody titersMultiple immunizations